Demand for Wegovy and other GLP-1 drugs used to treat obesity and diabetes has skyrocketed, but a new report suggests that many people may not be sticking with their weight-loss treatment long enough.
A new survey from Health found that many GLP-1 users still face stigma and judgment, even as the drugs become more common and ...
The use of drugs like Ozempic, Wegovy and Zepbound in people with type 1 diabetes has risen sharply over the past decade, a new study finds, even though there’s little information on the drugs’ safety ...
A majority of people with overweight or obesity prescribed glucagon-like peptide 1 receptor agonists (GLP-1 RAs) discontinue them within 1 year, with higher quit rates among those without type 2 ...
One in eight American adults have used a GLP-1 agonist. This class of drugs are prescribed for weight loss, to treat diabetes, and to reduce the risk of heart attack and stroke in adults with heart ...
When you start taking GLP-1s, you’re probably excited about the expected changes to your body. These medications were created to lower blood sugar for diabetes, but many are now popularly used for ...
Share on Pinterest An increasing number of people without diabetes are using GLP-1 agonist drugs for weight loss only. Image credit: MarkHatfield/Getty Images. The last few years have seen a marked ...
LAS VEGAS — Off-label use of GLP-1 drugs by people with type 1 diabetes (T1D) did not lead to diabetic ketoacidosis (DKA) or pancreatitis in a large 1-year single-center study. Moreover, GLP-1 agonist ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results